‘Power 25’ features New Haven healthcare figures
newhavenbiz has published Power25: Healthcare. Meet the Greater New Haven healthcare industry’s most powerful movers and shakers. more
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
newhavenbiz has published Power25: Healthcare. Meet the Greater New Haven healthcare industry’s most powerful movers and shakers. more
Cybrexa Therapeutics, an oncology-focused biotechnology company based in New Haven, has appointed pharmaceutical and financial services veteran Stephen Basso to serve as its chief financial...
Alexion Pharmaceuticals reports that the FDA has approved the expanded use of ULTOMIRIS® (ravulizumab-cwvz) to include children (one month of age and older) and adolescents with...
U.S. Senator Chris Murphy (D-Conn.) announced that CytoVeris, based in Farmington, has been named May’s “Innovator of the Month.” CytoVeris’ innovative technology, TumorMAP™ powered by OncoSight...
Intensity Therapeutics has announced data from its on-going Phase 1/2 clinical trial in refractory patients demonstrating efficacy and tolerability of INT230-6, either as monotherapy or...
Taconic Biosciences reports a significant enhancement to the Taconic-Cyagen Model Generation Alliance allowing seamless importation of new genetically engineered models originating in China under the...
Several of Connecticut’s public and private economic development organizations — including the Department of Economic and Community Development (DECD), AdvanceCT and MetroHartford Alliance — have...
Abbratech has leased a 5,000-square-foot space for research and development at 25 Business Park Drive, Branford. Founded in 2020, the company is working to apply...
Biohaven Pharmaceuticals has won FDA approval to market its new migraine pill Nurtec ODT as a preventative, giving the New Haven company the first drug...
New Haven’s BioXcel Therapeutics has taken a major step forward in its push to bring its first commercial drug to the marketplace. The FDA recently accepted...